Drug makers get sweeping immunity to pay patients into trials

What it does

This bill makes it easier for pharmaceutical and medical device companies to recruit and retain patients in clinical trials, especially from underrepresented populations. It does this by: (1) authorizing federal grants for community outreach and training to boost enrollment; (2) allowing companies to pay trial participants' travel, meals, and other expenses without triggering anti-kickback laws; (3) permitting companies to cover patients' insurance cost-sharing (copays, deductibles) during trials; and (4) making up to $2,000 per year in trial payments tax-free to participants. The bill frames these changes as diversity and access measures, but the primary beneficiaries are pharmaceutical and device manufacturers seeking to fill trials faster and cheaper.

Why we flagged it

While framed as a diversity and access measure, the bill's substantive mechanism is a broad exemption from anti-kickback and False Claims Act liability for pharmaceutical and device manufacturers paying patient expenses and cost-sharing during trials. This is functionally a regulatory carve-out that reduces compliance friction for an industry seeking to accelerate enrollment.

What the text implies

• Manufacturers gain financial leverage to preferentially enroll vulnerable or economically disadvantaged patients, potentially skewing trial demographics toward populations with fewer treatment alternatives and higher desperation to participate.
• The anti-kickback exemption (Section 4–5) is broadly written and may extend beyond the stated diversity purpose to routine trial recruitment, effectively narrowing enforcement of existing fraud statutes.

The full analysis lists 5 implications of this text.

Who stands to gain

pharmaceutical manufacturers; medical device manufacturers; contract research organizations